Kit for improving expression level of fetal hemoglobin in human red blood cells through base replacement and application
By using a single-base editor to disrupt the BCL11A enhancer region in hematopoietic stem cells, the problem of insufficient fetal hemoglobin expression was solved, and high expression of fetal hemoglobin in erythroid cells was achieved, providing an effective treatment option for thalassemia.
Patent Information
- Application Number
- CN202310588833.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
Current technologies are insufficient to effectively activate fetal hemoglobin expression in human red blood cells, resulting in limited treatment efficacy for hemoglobinopathies such as thalassemia.
Gene editing of the BCL11A enhancer region of hematopoietic stem cells was performed using a single-base editor to disrupt the binding of BCL11A to the HBG1/2 promoter and increase the expression level of fetal hemoglobin.
It significantly increased the expression of fetal hemoglobin in erythroid cells, providing a safe and effective treatment for thalassemia.
Smart Images

Figure HDA0004244779920000011 
Figure HDA0004244779920000012 
Figure HDA0004244779920000013
Abstract
Description
Technical Field
[0001] The present invention relates to a kit and application thereof for improving the expression level of fetal hemoglobin in human red blood cells by base substitution in the field of biomedicine. Background Art
[0002] Thalassemia is a single-gene inherited blood disease and one of the diseases with the highest incidence. The disease is mainly caused by abnormal globin synthesis caused by mutations in the α / β globin encoding genes. The clinical manifestations of patients with thalassemia are polarized, and the symptoms vary in severity. Patients with severe thalassemia require lifelong blood transfusions, but this method is expensive, has limited therapeutic effects, and can cause a variety of complications. Allogeneic hematopoietic stem cell transplantation is currently the only way to completely cure thalassemia, but there are problems such as matching difficulties and safety. Gene editing technology has brought hope to the treatment of thalassemia. Gene editing of hematopoietic stem cells from the patient's own source can avoid transplant rejection and other phenomena, achieving the goal of one-time treatment and lifelong cure.
[0003] Hemoglobin is a special protein responsible for transporting oxygen to red blood cells, which is composed of globin and heme. Globin is a tetramer composed of α and β chains, and the β chain is encoded by genes such as HBE, HBG1, HBG2, HBD, and HBB. Hemoglobin has different expressions at different stages of development, including embryonic, fetal, and adult hemoglobin, and is dynamically adjusted according to oxygen demand, which is called hemoglobin conversion. After birth, fetal hemoglobin is replaced by adult hemoglobin. Among them, the γ globin gene (HBG1 and HBG2) is usually expressed in the fetal liver, spleen, and bone marrow. Two γ chains and two α chains constitute fetal hemoglobin (HbF), which is usually replaced by adult hemoglobin (HbA) at birth. Adult hemoglobin consists of a pair of α chains and a pair of β chains (α2β2). HPFH is a hereditary continuous expression of fetal hemoglobin, which can alleviate the symptoms of patients with thalassemia, so activating the expression of fetal hemoglobin has become a new method for treating thalassemia.
[0004] With the continuous development of sequencing technology, researchers have discovered BCL11A, a key factor that affects the regulation of fetal hemoglobin. By genotyping 3,329 individuals, researchers found that the rs11886868 SNP on BCL11A was closely associated with fetal hemoglobin expression. Subsequent studies have shown that BCL11A, as a transcriptional repressor, inhibits the expression of fetal hemoglobin by acting together with other transcription factors, and can directly bind to the upstream of the transcription start of HBG1 / 2 to inhibit its transcription. By using gene editing technology, researchers successfully knocked out or disrupted the binding of BCL11A to the HBG1 / 2 promoter, effectively increasing the expression level of fetal hemoglobin in hematopoietic stem cells. However, since BCL11A is also expressed in non-erythroid cells, the method of treating thalassemia by destroying BCL11A is more limited. Red blood cells (i.e., erythroid cells) are the most numerous type of blood cells in human blood and are the medium for transporting oxygen in the body. Mature red blood cells are anucleate. Non-erythrocytes are blood cells other than red blood cells, such as white blood cells, T cells, etc. Non-erythrocytes play an important role in immune regulation, etc. Activating the expression of fetal hemoglobin in red blood cells and then transfusing it back into the body has become a safe and effective treatment for thalassemia. Summary of the invention
[0005] The technical problem to be solved by the present invention is how to prepare erythroid cells with low expression of BCL11A and high expression of fetal hemoglobin.
[0006] In order to solve the above technical problems, the present invention first provides a method for preparing erythroid cells with high expression of fetal hemoglobin, the method comprising:
[0007] 1) Gene-editing the BCL11A enhancer region of isolated hematopoietic stem cells using a single base editor to obtain gene-edited cells;
[0008] 2) performing erythroid differentiation on the gene-edited cells to obtain erythroid cells with high expression of fetal hemoglobin.
[0009] In the above method, the single-base editor may be a cytosine editor.
[0010] In step 1) of the above method, the target sequence of the sgRNA for gene editing may be sequence 1, sequence 2, sequence 3 and / or sequence 4.
[0011] The sgRNA can be obtained by inserting sequence 1, sequence 2, sequence 3 and / or sequence 4 into the vector shown in sequence 5 for transcription, or can be directly synthesized.
[0012] In the above method, the single base editor can be a fusion protein formed by APOBEC, Cas9n, UGI and eGFP.
[0013] The fusion protein can be obtained by introducing the vector shown in sequence 6 in the sequence table into cells for protein expression.
[0014] In the above method, part or all of the C in the target sequence in the gene-edited cell is edited to T.
[0015] In the above method, the hematopoietic stem cells may be CD34+ hematopoietic stem cells.
[0016] In the above method, the hematopoietic stem cells may be human hematopoietic stem cells.
[0017] The fetal hemoglobin-high-expressing erythroid cells obtained by the method for preparing fetal hemoglobin-high-expressing erythroid cells also fall within the protection scope of the present invention.
[0018] The present invention also provides a kit, which comprises 1) and 2):
[0019] 1) 11), 12) or 13) below:
[0020] 11) The single base editor;
[0021] 12) A nucleic acid molecule containing the single-base editor;
[0022] 13) an expression cassette, recombinant vector, microorganism or cell line containing the nucleic acid molecule described in 12);
[0023] 2) 21), 22) or 23) below:
[0024] 21) sgRNA targeting the BCL11A enhancer region;
[0025] 22) transcribing the nucleic acid molecule of the sgRNA described in 21);
[0026] 23) An expression cassette, recombinant vector, microorganism or cell line containing the nucleic acid molecule described in 22).
[0027] In the above kit, the target sequence of the sgRNA may be sequence 1, sequence 2, sequence 3 and / or sequence 4.
[0028] In the above kit, the recombinant vector described in 13) can be as shown in Sequence 6.
[0029] 23) The recombinant vector can be obtained by inserting the target sequence into the vector shown in sequence 5.
[0030] The kit may consist of the above 1) and 2).
[0031] The use of the kit in preparing erythroid cells with high expression of fetal hemoglobin also falls within the protection scope of the present invention.
[0032] In the present invention, the single base editor can be any system that can realize single gene editing. For example, a single gene editor that edits C to T or G to A. The single base editor can be a single base editor RNP (YP485), or other existing cytosine editor (CBE) plasmids, such as pCMV_AncBE4max_P2A_GFP, pCAG-CBE4max-SpRY-P2A-EGFP, pCMV_AncBE4max, etc.).
[0033] The present invention uses a base editing tool (YP485) combined with a specific sgRNA to directional destroy the BCL11A enhancer region in hematopoietic stem cells (HSC). Without causing double-strand breaks in DNA, the C in the region is edited to T or G is edited to A, thereby increasing the expression level of γ-globin in human red blood cells. This technology can provide a reliable method and reagent for treating hemoglobinopathies. The present invention can be used to treat hemoglobinopathies such as β-thalassemia and sickle cell disease.
[0034] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 Schematic diagram of the main expression elements of single-base editors.
[0036] Figure 2 Human hematopoietic stem cell isolation.
[0037] Figure 3 Detection of human hematopoietic stem cell markers.
[0038] Figure 4 Editing rate detection (edited sequence). The upper left, upper right, lower left, and lower right figures are the sequencing results of gene-edited cells with target sequences of 5522, 5534, 5546, and 5568, respectively. The data under each site in the figure indicates the percentage of the corresponding nucleotide appearing at the site, which is the editing rate.
[0039] Figure 5 Human hematopoietic stem cell erythroid differentiation experiment. The following figure is a representative picture of Giemsa staining at each stage, where pink represents cytoplasm and dark red represents cell nucleus.
[0040] Figure 6Human fetal hemoglobin detection. A: Q-PCR test results of HBG1 / 2 and HBB expression levels; B: WB test results of γglobin expression levels; C: WB test results of BCL11A expression levels. Among them, HUDEP-2 represents HUDEP-2 (Human Umbilical Cord Derived Erythroid Progenitor 2 cells, human umbilical cord-derived erythroid progenitor cells); this kit represents cells after the BCL11A enhancer region of the present invention is edited and erythroid differentiation is performed; control represents cells after electroporation of the control sgRNA plasmid during gene editing and erythroid differentiation is performed.
[0041] Figure 7 The kit of the present invention affects cell activity and can significantly improve the expression of fetal hemoglobin. A is a cell activity test, using the Cell Counting Kit-8, a product of Beyotime, with the catalog number C0038. The meaning of the horizontal axis is: the concentration of transfected RNP used. B is a cell counting experiment statistic, and the cell counting adopts the traditional manual counting method. The horizontal axis is the time after transfection, and the 0th day is recorded from the beginning of transfection. C is the result of Giemsa staining of hematopoietic stem cells, using the product of Beyotime, with the catalog number C0133-100ml. D is the result of peroxidase staining of cells after differentiation of hematopoietic stem cells, using the product of Solebao, with the catalog number G2370-4×20ml. HUDEP-2 stands for Human Umbilical Cord Derived Erythroid Progenitor 2 cells; this kit represents cells after the BCL11A enhancer region of the present invention is edited and erythroid differentiation is performed; the control represents cells after the control sgRNA plasmid is electroporated during gene editing and erythroid differentiation is performed. DETAILED DESCRIPTION
[0042] The experimental methods in the following examples are conventional methods unless otherwise specified, and are performed according to the techniques or conditions described in the literature in the art or according to the product instructions. The materials, reagents, instruments, etc. used in the following examples are all commercially available unless otherwise specified. The quantitative tests in the following examples were repeated three times, and the results were averaged.
[0043] Embodiment 1,
[0044] 1. Acquisition of single-base editor RNP (YP485)
[0045] CAG-FNLS-BE3-YE1-P2A-GFP (YP485 plasmid, the sequence of which is shown as SEQ ID No. 6 in the sequence table) was introduced into RIPL-BL21 (DE3)-competent cells (Thermo Fisher, EC0114). Grow in TB medium (Sigma, T5574-500ML) at 37°C and switch to 15°C. Induce cells with 1mM isopropyl β-d-1-thiogalactoside (Solebol, I8070) for 16-20 hours, collect cell paste, and lyse in PBS buffer containing 500mM NaCl and 10% glycerol using a microfluidic instrument. The lysate was centrifuged at 18,000g for 40 minutes. The protein was purified using a nickel affinity column, a cation exchange column, and a Superdex 200 size exclusion column in sequence. The purified protein was concentrated in 30 mM HEPES buffer at pH 7.4 containing 150 mM sodium chloride and 10% glycerol. Protein samples and fractions were separated by SDS-PAGE and stained with GelCodeBlue Stain Reagent (Fisher). The resulting protein was the single-base editor RNP (YP485), the fusion protein formed by APOBEC, Cas9n, UGI and eGFP ( Figure 1 ).
[0046] In SEQ ID No.6, positions 2771-3025 show the DNA sequence of APOBEC, positions 3128-7228 show the DNA sequence of Cas9n, positions 7241-7489 show the DNA sequence of UGI, and positions 7595-98314 show the DNA sequence of eGFP.
[0047] 2. sgRNA plasmid construction
[0048] Design sgRNA targets for targeting and regulating the enhancer region of fetal hemoglobin BCL11A. After synthesizing oligos, anneal and connect to the sgRNA expression vector (sgRNA-BSPQ1-mCHenry). The resulting recombinant plasmids are named sgRNA-5522, sgRNA-5534, sgRNA-5546, and sgRNA-5568. Each plasmid can transcribe the sgRNA targeting and regulating the enhancer region of fetal hemoglobin BCL11A. The control sgRNA target sequence is used as a control, and the resulting recombinant plasmid is recorded as the control sgRNA plasmid. The sequences of each target are as follows:
[0049] 5522: 5′-aggggtcccacaagatcaca-3′ (SEQ ID No. 1);
[0050] 5534: 5′-gtgcatcttgtgtgcttggt-3′ (SEQ ID No. 2);
[0051] 5546: 5′-ggccctggacactgaaggct-3′ (SEQ ID No. 3);
[0052] 5568: 5′-catcactcttagcagggctg-3′ (SEQ ID No. 4).
[0053] Control sgRNA target sequence: ccttattcccttttttgcgg (located in the prokaryotic ampicillin expression gene, will not target eukaryotic genes, and therefore will not edit sequences that may increase fetal hemoglobin expression).
[0054] Among them, the sequence of sgRNA-BSPQ1-mCHenry is shown as SEQ ID No.5 in the sequence table.
[0055] 3. Cell Transfection
[0056] (1) With informed consent from volunteers, CD34+ hematopoietic stem cells were isolated from human peripheral blood (or CD34+ hematopoietic stem cells were purchased from commercial sources). Hematopoietic stem cells were enriched using Miltenyi CD34 Microbead Kit (Miltenyi Biotec) to obtain CD34+ hematopoietic stem cells. Hematopoietic stem cells were cultured and cryopreserved using the X-VIVO 15 (04-418Q, Lonza) kit. Figure 2 ) detected human hematopoietic stem cell markers CD235a and CD71, and the results were as follows Figure 3 shown.
[0057] (2) Using Lonza 4D Nucleofector (V4XP-3024), sgRNA-5522, sgRNA-5534, sgRNA-5546, sgRNA-5568 or control sgRNA plasmids together with protein RNP expressing the single base editing system were electroporated into CD34+ hematopoietic stem cells using the EO-100 program. After electroporation, the cells were cultured using X-VIVO medium.
[0058] (3) Five days after electroporation, the hematopoietic stem cell genome was extracted. The corresponding primers were designed for PCR sequencing. The sequencing results were analyzed using the website https: / / hanlab.cc / beat / and EditR software.
[0059] The sequencing results of CD34+ hematopoietic stem cells after the BCL11A enhancer region was edited are shown in Figure 4 , in which the target sequence has C edited to T or G edited to A.
[0060] 4. Detection of fetal hemoglobin expression level
[0061] The hematopoietic stem cells edited in step 2 were subjected to in vitro differentiation experiments, and then protein immunoblotting (Western Blot, WB) and Q-PCR were performed to detect the expression levels of BCL11A, HBG1 / 2, and HBB.
[0062] 1. Erythroid differentiation of hematopoietic stem cells ( Figure 5 )
[0063] Differentiation process Figure 5 shown.
[0064] Preparation of hematopoietic stem cell erythroid differentiation medium (EDM): IMDM medium was supplemented with 330μg / mL holo-Transferrin, 10μg / mL Recombinant Human Insulin, 2IU / mL Heparin, 5% Human blood type AB plasma, 3IU / mL EPO, 1% L-glutamine and 1% penicillin / streptomycin.
[0065] EDM I: used for differentiation culture day 0-4, with 100 ng / mL SCF and 1 μg / mL Dox added to EDM.
[0066] EDM II: Use after 4-8 days of differentiation culture. Add 1 μg / mL Dox to EDM.
[0067] EDM III: used after the 8th day of differentiation culture, EDM is denoted as EDM III, and no additional factors are added.
[0068] Resuspend the hematopoietic stem cells edited in step 2 and add them to the erythroid differentiation medium EDM I. The cell density is about 5×10 per ml. 4 -2×10 5 The cells were cultured in EDMI medium until day 4, then centrifuged and added to EDM II at a cell density of approximately 5 × 10 per ml. 4 -2×10 5 The cells were cultured in EDM II medium until day 8, then centrifuged and transferred to EDM III at a cell density of approximately 1 × 10 per ml. 6 The cells were cultured in EDM III medium until day 12, completing the erythroid differentiation of hematopoietic stem cells.
[0069] Representative images of Giemsa staining of cells at each stage, where pink represents cytoplasm and dark red represents nuclei ( Figure 5 ).
[0070] 2.WB and Q-PCR
[0071] Total protein and total RNA of cells after erythroid differentiation were extracted, and WB and Q-PCR were used to detect the expression of fetal hemoglobin and BCL11A after gene editing of genetically modified hematopoietic stem cells ( Figure 6 HUDEP-2 (Human Umbilical Cord Derived Erythroid Progenitor 2 cells) was used as a control.
[0072] The results showed that the expression level of BCL11A decreased significantly; the expression level of γglobin increased significantly, indicating that the expression level of fetal hemoglobin increased significantly; the expression level of HBG1 / 2 increased significantly, and the expression level of HBB decreased significantly.
[0073] The antibodies used in WB are: γglobin antibody (Santa Cruz, sc-21756), BCL11A antibody (Santa Cruz product, catalog number sc-514842), GAPDH (Abcam product, catalog number ab8245).
[0074] The primers used for Q-PCR are as follows:
[0075] HBG1 / 2: F: GGAAGATGCTGGAGGAGAAACC; R: GTCAGCACCTTCTTGCCATGTG;
[0076] HBB: F: CACCTTTGCCACACTGAGTGAG; R: CCACTTTCTGATAGGCAGCCTG.
[0077] 3. Detection of Cell Activity
[0078] Cell activity detection was performed using Cell Counting Kit-8 (Cat. No. C0038) produced by Bio-Time, Inc. HUDEP-2 (Human Umbilical Cord Derived Erythroid Progenitor 2 cells) was used as a control.
[0079] The experimental results are as follows Figure 7 The results show that the erythroid cells obtained by the present invention have good activity.
[0080] The SEQ ID No.5 and SEQ ID No.6 involved in the above embodiment are as follows:
[0081] SEQ ID No.5(sgRNA-BSPQ1-mCHenry):
[0082]
[0083] SEQ ID No.6 (YP485 plasmid):
[0084]
[0085] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. A method for preparing erythroid cells with high expression of fetal hemoglobin, include: 1) Gene-editing the BCL11A enhancer region of isolated hematopoietic stem cells using a single base editor to obtain gene-edited cells; 2) performing erythroid differentiation on the gene-edited cells to obtain erythroid cells with high expression of fetal hemoglobin.
2. The method according to claim 1, Features: The single base editor is a cytosine editor.
3. The method according to claim 1 or 2, Features: In step 1), the target sequence of the sgRNA for gene editing is sequence 1, sequence 2, sequence 3 and / or sequence 4.
4. The method according to any one of claims 1 to 3, Features: The single-base editor is a fusion protein formed by APOBEC, Cas9n, UGI and eGFP.
5. The method according to any one of claims 1 to 4, Features: The hematopoietic stem cells are CD34+ hematopoietic stem cells.
6. The method according to any one of claims 1 to 5, Features: The hematopoietic stem cells are human hematopoietic stem cells.
7. Erythroid cells highly expressing fetal hemoglobin obtained by the method according to any one of claims 1 to 6.
8. A kit, Features: The kit contains 1) and 2): 1) 11), 12) or 13) below: 11) The single base editor according to any one of claims 1 to 4; 12) A nucleic acid molecule containing the single-base editor; 13) an expression cassette, recombinant vector, microorganism or cell line containing the nucleic acid molecule described in 12); 2) 21), 22) or 23) below: 21) sgRNA targeting the BCL11A enhancer region; 22) transcribing the nucleic acid molecule of the sgRNA described in 21); 23) An expression cassette, recombinant vector, microorganism or cell line containing the nucleic acid molecule described in 22).
9. The kit according to claim 8, Features: The target sequence of the sgRNA is sequence 1, sequence 2, sequence 3 and / or sequence 4.
10. Use of the kit according to claim 8 or 9 in preparing erythroid cells with high expression of fetal hemoglobin.
